B G M Durie

Summary

Affiliation: St. Vincent's Comprehensive Cancer Center
Country: USA

Publications

  1. doi Role of new treatment approaches in defining treatment goals in multiple myeloma--the ultimate goal is extended survival
    Brian G M Durie
    Cedars Sinai Samuel Oschin Cancer Center, CA, USA
    Cancer Treat Rev 36:S18-23. 2010
  2. pmc Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival
    Brian Van Ness
    Cancer Center, University of Minnesota, Minneapolis, MN, USA
    BMC Med 6:26. 2008
  3. pmc Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma
    B G M Durie
    Hematology Oncology, Cedars Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute and Aptium Oncology, Los Angeles, CA 90048, USA
    Leukemia 23:1913-9. 2009
  4. ncbi International uniform response criteria for multiple myeloma
    B G M Durie
    Aptium Oncology, Inc, Cedars Sinai Outpatient Cancer Center, Los Angeles, CA 90048, USA
    Leukemia 20:1467-73. 2006
  5. ncbi The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system
    Brian G M Durie
    Cedars Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute, Division of Hematology Oncology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Eur J Cancer 42:1539-43. 2006
  6. ncbi New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals
    Brian G M Durie
    Department of Medicine, Division of Hematology Oncology, Cedars Sinai Outpatient Cancer Center, Los Angeles, CA 90048 1804, USA
    Clin Lymphoma Myeloma 6:181-90. 2005
  7. ncbi Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
    Sundar Jagannath
    St Vincent s Comprehensive Cancer Center, New York, NY 10011 8202, USA
    Br J Haematol 129:776-83. 2005
  8. ncbi Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation
    Brian G M Durie
    Cedars Sinai Comprehensive Cancer Center, Los Angeles, CA, USA
    Hematol J 4:379-98. 2003
  9. doi Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma
    Sundar Jagannath
    St Vincent s Comprehensive Cancer Center, New York, NY 10011, USA
    Br J Haematol 146:619-26. 2009
  10. ncbi Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials
    Brian G M Durie
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Clin Oncol 22:1857-63. 2004

Collaborators

Detail Information

Publications24

  1. doi Role of new treatment approaches in defining treatment goals in multiple myeloma--the ultimate goal is extended survival
    Brian G M Durie
    Cedars Sinai Samuel Oschin Cancer Center, CA, USA
    Cancer Treat Rev 36:S18-23. 2010
    ..Therefore, at this time, extended survival should remain the goal of myeloma therapy...
  2. pmc Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival
    Brian Van Ness
    Cancer Center, University of Minnesota, Minneapolis, MN, USA
    BMC Med 6:26. 2008
    ..To explore SNP associations with PFS we compared SNP profiles of short term (less than 1 year, n = 70) versus long term progression-free survivors (greater than 3 years, n = 73) in two phase III clinical trials...
  3. pmc Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma
    B G M Durie
    Hematology Oncology, Cedars Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute and Aptium Oncology, Los Angeles, CA 90048, USA
    Leukemia 23:1913-9. 2009
    ..0074); Gsk3beta (P=0.02) and TNFSF8 (P=0.04) were linked to bone disease. This assessment of genetic polymorphisms identifies SNPs with both potential biological relevance and utility in prognostic models of myeloma bone disease...
  4. ncbi International uniform response criteria for multiple myeloma
    B G M Durie
    Aptium Oncology, Inc, Cedars Sinai Outpatient Cancer Center, Los Angeles, CA 90048, USA
    Leukemia 20:1467-73. 2006
    ..It is anticipated that the International Response Criteria for multiple myeloma will be widely used in future clinical trials of myeloma...
  5. ncbi The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system
    Brian G M Durie
    Cedars Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute, Division of Hematology Oncology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Eur J Cancer 42:1539-43. 2006
    ..Wider use of newer imaging will undoubtedly enhance analysis of new trials incorporating novel agents...
  6. ncbi New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals
    Brian G M Durie
    Department of Medicine, Division of Hematology Oncology, Cedars Sinai Outpatient Cancer Center, Los Angeles, CA 90048 1804, USA
    Clin Lymphoma Myeloma 6:181-90. 2005
    ..Fortunately, new agents already offer longer-term disease control. The ongoing search for a cure will undoubtedly demand courage and dedication on the part of investigators and patients...
  7. ncbi Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
    Sundar Jagannath
    St Vincent s Comprehensive Cancer Center, New York, NY 10011 8202, USA
    Br J Haematol 129:776-83. 2005
    ..Bortezomib alone or in combination with dexamethasone is an effective induction therapy with a high CR and nCR rate and manageable toxicities in previously untreated patients with myeloma...
  8. ncbi Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation
    Brian G M Durie
    Cedars Sinai Comprehensive Cancer Center, Los Angeles, CA, USA
    Hematol J 4:379-98. 2003
    ..2. Staging and prognostic factors. 3. Frontline therapy. 4. High-dose therapy and transplant. 5. Maintenance therapy. 6. Supportive care and management of specific complications. 7. Novel therapies and new technologies...
  9. doi Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma
    Sundar Jagannath
    St Vincent s Comprehensive Cancer Center, New York, NY 10011, USA
    Br J Haematol 146:619-26. 2009
    ..Bortezomib +/- dexamethasone is an effective and well-tolerated induction regimen for the frontline treatment of MM...
  10. ncbi Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials
    Brian G M Durie
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Clin Oncol 22:1857-63. 2004
    ..The purpose was to clarify the predictive value of specific levels of myeloma-associated monoclonal protein reduction and time to first progression using mature data sets...
  11. ncbi Whole-body (18)F-FDG PET identifies high-risk myeloma
    Brian G M Durie
    Division of Hematology Oncology, Department of Medicine, Cedars Sinai Comprehensive Cancer Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    J Nucl Med 43:1457-63. 2002
    ..The purpose of this study was to evaluate the clinical utility of whole-body PET with (18)F-FDG in patients with multiple myeloma and related monoclonal diseases...
  12. ncbi Low-dose thalidomide in myeloma: efficacy and biologic significance
    Brian G M Durie
    Cedars Sinai Comprehensive Cancer Center, Los Angeles, CA, USA
    Semin Oncol 29:34-8. 2002
    ..The median effective dose of thalidomide was 200 mg/d. Thalidomide's mechanism of action, particularly its effects on macrophages, is described. Current approaches to single-agent and combination therapy are presented...
  13. doi Myeloma therapy: 25 years forward--immune modulation then and now
    Brian G M Durie
    Cedars Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute, Hematology Oncology and Aptium Oncology, Los Angeles, CA, USA
    J Clin Oncol 26:4698-700. 2008
  14. ncbi Treatment of myeloma--are we making progress?
    Brian G M Durie
    N Engl J Med 359:964-6. 2008
  15. ncbi Management of multiple myeloma: a systematic review and critical appraisal of published studies
    Ambuj Kumar
    Interdisciplinary Oncology Program of the H Lee Moffitt Cancer and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Lancet Oncol 4:293-304. 2003
    ..We conclude that the quality of total evidence supporting treatment recommendations in myeloma is modest at best and has an ample scope for improvement...
  16. ncbi Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis
    Jeffrey A Zonder
    Blood 108:403; author reply 404. 2006
  17. doi Eliminating the complete response penalty from myeloma response criteria
    S Vincent Rajkumar
    Blood 111:5759-60. 2008
  18. doi Oncology nurses take the lead in providing novel therapy guidelines for multiple myeloma
    Brian G M Durie
    Clin J Oncol Nurs 12:7-8. 2008
  19. doi Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma
    Vania T M Hungria
    Haematologica 93:791-2. 2008
  20. doi Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
    Heinz Ludwig
    Department of Medicine, Wilhelminenspital, Montleartstr 37, 1160 Vienna, Austria
    Blood 111:4039-47. 2008
    ....
  21. ncbi Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement
    Brian G M Durie
    Mayo Clin Proc 82:516-7; author reply 517-8. 2007
  22. ncbi A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience
    Joth L Jacobson
    Southwest Oncology Group Statistical Center, Seattle, WA 98101 1468, USA
    Br J Haematol 122:441-50. 2003
    ..Additional evaluation in other MM patient populations is needed to confirm results...
  23. ncbi Osteonecrosis of the jaw and bisphosphonates
    Brian G M Durie
    N Engl J Med 353:99-102; discussion 99-102. 2005
  24. ncbi International staging system for multiple myeloma
    Philip R Greipp
    Mayo Clinic College of Medicine and Eastern Cooperative Oncology Group, Rochester, MN, USA
    J Clin Oncol 23:3412-20. 2005
    ..There is a need for a simple, reliable staging system for multiple myeloma that can be applied internationally for patient classification and stratification...